Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 2,101–2,200 of 4,275
Torti, D., Sassi, F. P., Galimi, F., Gastaldi, S., Perera, T. P. S., Comoglio, P. M., Trusolino, L., & Bertotti, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26137 · Cited by 22
“Both cytokines are transcriptionally upregulated by Ras-dependent signals, which are the major transducers of Metdriven growth in Met-addicted cancer cells.(14,24,25) They are involved in the progression of different types of tumors by stimulating angiogenesis and inflammatory reactions within the tumor reactive micro…”
BackgroundThe Dynamic Process and Its Dual Effects on Tumors of Therapy-Induced Senescence
Liao, C., Xiao, Y., & Liu, L. (2020) · Cancer Management and Research · doi:10.2147/cmar.s285083 · Cited by 26
“The SASP factors from malignant tumor cells can alter the tissue microenvironment, thus creating a local region of the tumor-promoting microenvironment that stimulates nearby premalignant and malignant cells metastasis and invasion.(12) Chemotherapy-”
BackgroundDiverse pathways to neuronal necroptosis in Alzheimer's disease
Jayaraman, A., & Reynolds, R. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15662 · Cited by 23
“The number of senescent cells increases with ageing, and these cells secrete several proinflammatory cytokines, which affect other cells in their vicinity (Coppé et al., 2008).”
BackgroundRemodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer
He, Y., Qiu, Y., Yang, X., Lu, G., & Zhao, S. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.11.002 · Cited by 25
LncRNAs: the missing link to senescence nuclear architecture
Han, J. J. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2023.03.007 · Cited by 27
Zhao, X., Kang, J., & Zhao, R. (2018) · Oncology Letters · doi:10.3892/ol.2018.9084 · Cited by 22
“Including the upregulation of immunogenic surface molecules after RT and antigen processing and Modulation the tumor microenvironment via secreted factors (6,7).”
Guo, Y., Chomiak, A. A., Hong, Y., Lowe, C. C., Kopsidas, C. A., Chan, W., Andrade, J., Pan, H., Zhou, X., Monuki, E. S., et al. (2021) · iScience · doi:10.1016/j.isci.2022.104519 · Cited by 24
“…metabolic profiles, resistance to apoptosis, increases in autophagy, and implementation of a complex and multicomponent secretome known as the senescence-associated secretory phenotypes (SASP) (Campisi and Robert, 2014; Coppe et al., 2008; Munoz-Espin and Serrano, 2014; Rodier and Campisi, 2011).”
BackgroundLimited cell-autonomous anticancer mechanisms in long-lived bats
Athar, F., Zheng, Z., Riquier, S., Zacher, M., Lu, J. Y., Zhao, Y., Volobaev, V. P., Alcock, D., Galazyuk, A. V., Cooper, L. N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59403-z · Cited by 30
Kouroumalis, A., Mavrogonatou, E., Savvidou, O. D., Papagelopoulos, P. J., Pratsinis, H., & Kletsas, D. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2018.05.007 · Cited by 23
Zhang, S., Zeng, N., Alowayed, N., Singh, Y., Cheng, A., Lang, F. J. W., & Salker, M. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183681 · Cited by 25
Donor and Recipient Age-Mismatches: The Potential of Transferring Senescence
Iske, J., Matsunaga, T., Zhou, H., & Tullius, S. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.671479 · Cited by 24
“Senescent cells exhibit a distinct, pro-inflammatory secretome consisting of cytokines (IL-6, IL-8, TNF-a), chemokines (CCL2, CCL20) and matrix remodeling enzymes termed the “Senescent Associated Secretory Phenotype” (SASP) (25).”
BackgroundInfluentialChrienová, Ž., Rysanek, D., Olekšák, P., Stary, D., Bajda, M., Reiniš, M., Mikyšková, R., Novotny, O., Andrýs, R., Skarka, A., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1048260 · Cited by 28
“Thus, compounds modulating the senescent secretome seem to be the better alternative, since the production of factors secreted by senescent cells termed senescence-associated secretory phenotype (SASP) is considered a primary mediator of the detrimental effects of senescent cells (Coppé et al., 2008; Wang et al., 2017…”
BackgroundKuźnar-Kamińska, B., Mikuła-Pietrasik, J., Witucka, A., Romaniuk, A., Konieczna, N., Rubiś, B., Książek, K., Tykarski, A., & Batura-Gabryel, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-31037-w · Cited by 22
Salas, S. S., Arroyave-Ospina, J. C., Zhang, M., Damba, T., Buist‐Homan, M., Muñoz‐Ortega, M. H., Ventura‐Juárez, J., & Moshage, H. J. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111617 · Cited by 23
Broderick, C., Mezzadra, R., Sisso, E. M., Mbuga, F., Raghulan, R., Perez, A. C., Kulick, A. R., Jiang, L., Jiang, J., Ho, Y.-J., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1425 · Cited by 32
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights
Li, X., & Zhao, H. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00603-0 · Cited by 26
“Moreover, IL-6 and IL-8 are secreted by stromal fibroblasts in various cancer types and are implicated in senescence-related secretory phenotypes [234–237].”
Mutant p53 as an Antigen in Cancer Immunotherapy
Sobhani, N., D’Angelo, A., Wang, X., Young, K. H., Generali, D., & Li, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114087 · Cited by 25
“These senescent cells produce a high number of interleukins and cytokines, attracting thereby CD-8 killer T cells, NK cells, macrophages and monocytes, which kill senescent cells [88].”
BackgroundExtracellular Vesicles in Pathophysiology: A Prudent Target That Requires Careful Consideration
Shahi, S., Kang, T., & Fonseka, P. (2024) · Cells · doi:10.3390/cells13090754 · Cited by 28
“For example, various cancers utilize EVs as a means to communicate with distant skeletal muscles and adipose tissues to induce muscle wasting and lipolysis, respectively, and triggers the onset of cancer-associated cachexia [166].”
BackgroundRole of low-dose radiation in senescence and aging: A beneficial perspective
Xu, J., Liu, D., Zhao, D., Jiang, X. M., Meng, X., Jiang, L., Meina, Y., Zhang, L., & Jiang, H. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120644 · Cited by 32
Zhao, H., Zhang, Y., Ren, Y., & Wang, W. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.13.12 · Cited by 29
“28,29 An experimental data study shows that SASP was elevated in the lacrimal gland of chronic graft-versus-host disease (cGVHD) mice compared with control mice.”
Ansermino, C., Pavlović, R., Braccia, C., Drago, D., Anelli, C., & Andolfo, A. (2026) · Biomarker Research · doi:10.1186/s40364-025-00889-6 · Cited by 27
“Finally, EVs are increasingly linked to aging, as their abundance and cargo composition shift with age, influencing cellular senescence, neurotrophic support and systemic inflammatory status [77, 78] (Fig.”
Cell enlargement modulated by GATA4 and YAP instructs the senescence-associated secretory phenotype
Joung, J., Heo, Y., Kim, Y., Kim, J., Choi, H., Jeon, T., Jang, Y., Kim, E.-J., Lee, S. H., Suh, J. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56929-0 · Cited by 29
Therapy-Induced Senescence: Novel Approaches for Markers Identification
Pacifico, F., Magni, F., Leonardi, A., & Crescenzi, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158448 · Cited by 30
Senescence as a modulator of oral squamous cell carcinoma development
Parkinson, E. K. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2009.09.009 · Cited by 25
GRSF1 suppresses cell senescence
Noh, J. H., Kim, K. M., Idda, M. L., Martindale, J. L., Yang, X., Abdelmohsen, K., & Gorospe, M. (2018) · Aging · doi:10.18632/aging.101516 · Cited by 24
“Thus, our findings that GRSF1 prevents SASP-associated IL6 production offer valuable insight into the role of mitochondria in cell senescence and organismal aging [8,21].”
BackgroundInfluentialAiding and Abetting: How the Tumor Microenvironment Protects Cancer from Chemotherapy
Fiedler, E. C., & Hemann, M. T. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055524 · Cited by 25
“This permanent cell cycle arrest is accompanied by a secretory program termed the senescence-associated secretory phenotype (SASP) (Coppé et al. 2008, Krizhanovsky et al. 2008, Davalos et al. 2010, Sun et al. 2012, Pérez-Mancera et al. 2014).”
BackgroundSenolytics rejuvenate aging cardiomyopathy in human cardiac organoids
Scalise, M., Cianflone, E., Quercia, C., Pagano, L., Chiefalo, A., Stincelli, A., Torella, A., Puccio, B., Santamaria, G., Guzzi, H. P., et al. (2025) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.112007 · Cited by 24
Transcriptome analysis and tumor suppressor requirements of STAT5‐induced senescence
Mallette, F. A., Moiseeva, O. V., Calabrese, V., Mao, B., Gaumont‐Leclerc, M., & Ferbeyre, G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05192.x · Cited by 22
Panchanathan, R., Ramalingam, V., Liu, H., & Choubey, D. (2021) · Life · doi:10.3390/life11040366 · Cited by 20
“This phenotype of senescent cells has been termed senescence-associated secretory phenotype (SASP) and the phenotype is thought to contribute to aging-related chronic inflammation [25,26].”
BackgroundIskandar, M., Barbero, M. X., Jaber, M. T., Chen, R., Gomez-Guevara, R., Cruz, E., & Westerheide, S. D. (2025) · Cancers · doi:10.3390/cancers17020257 · Cited by 34
IFN-γ induces senescence-like characteristics in mouse bone marrow mesenchymal stem cells
Zhou, Y., Mao, G. X., Zhang, J., Wen, X. L., Jia, B., Bao, Y. Z., Lv, X. L., Wang, Y. Z., & Wang, G. F. (2017) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/61431 · Cited by 25
“21 SASP is controlled by NF-κB, and could exacerbate cellular senescence.”
BackgroundBrain macrophage senescence in glioma
Li, L., Zhang, T. C., Xiao, M., Lu, Y., & Gao, L. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.07.005 · Cited by 24
Alhaddad, L., Osipov, A. N., & Leonov, S. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113577 · Cited by 22
“It has been suggested that IR likely triggers SASP induction in GBM cells via activation of NFκB signaling [508].”
BackgroundInfluentialDedifferentiation and in vivo reprogramming of committed cells in wound repair (Review)
Guo, Y., Wu, W., Yang, X., & Fu, X. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12886 · Cited by 27
Characterization of the EBV-Induced Persistent DNA Damage Response
Hafez, A. Y., & Luftig, M. A. (2017) · Viruses · doi:10.3390/v9120366 · Cited by 21
Cotarelo, C., Schad, A., Kirkpatrick, C. J., Sleeman, J. P., Springer, E., Schmidt, M., & Thaler, S. (2016) · Oncotarget · doi:10.18632/oncotarget.12432 · Cited by 23
“Many SASP components are protumorigenic growth factors, proteases or cytokines known to stimulate the aggressive behaviour of cancer cells in vitro [21–23].”
BackgroundSulicka‐Grodzicka, J., Surdacki, A., Seweryn, M. T., Mikolajczyk, T. P., Rewiuk, K., Guzik, T. J., & Grodzicki, T. K. (2021) · Cancer Medicine · doi:10.1002/cam4.3788 · Cited by 26
Parikh, N., Shuck, R. L., Nguyen, T., Herron, A. J., & Donehower, L. A. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0089 · Cited by 22
Guo, G., Watterson, S., Zhang, S., Bjourson, A. J., McGilligan, V., Peace, A. J., & Singh, T. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101363 · Cited by 25
“matory cytokines, growth factors, immune modulators and malignancy associate factors increased in vitro (Coppé et al., 2008).”
BackgroundEvidence of cellular senescence during the development of estrogen-induced pituitary tumors
Sabatino, M. E., Petiti, J. P., Sosa, L. D. V., Pérez, P. A., Gutiérrez, S., Leimgruber, C., Latini, A., Torres, A. I., & Paul, A. L. D. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0333 · Cited by 28
“In fact, senescent cells undergo extensive gene expression changes that emulate the inflammatory response, thereby developing a complex senescence-associated secretory phenotype (SASP), in vitro and in vivo, associated with the activation of nuclear factor kappa B (NFkB) or C/EBPB (Coppe et al. 2008).”
BackgroundThe non-modifiable factors age, gender, and genetics influence resistance exercise
Viecelli, C., & Ewald, C. Y. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.1005848 · Cited by 27
Ramos, A. M., Fernández‐Fernández, B., Pérez-Gómez, M. V., Julio, S. M. C., Sánchez-Niño, M. D., Sanz, A. B., Ruiz‐Ortega, M., & Ortíz, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1690450 · Cited by 25
“Key features of senescence include increased expression of cyclin dependent kinase inhibitors (p53, p21CIP1 and p16INK4a), morphologic and epigenetic changes, like senescence-associated heterochromatic foci, and the senescenceassociated secretory phenotype (SASP), consisting of increased production of profibrotic and…”
BackgroundKim, H. J., Kim, B., Byun, H. J., Yu, L., Nguyen, T. M., Nguyen, T. H., Do, P. A., Kim, E. J., Cheong, K. A., Kim, K. S., et al. (2021) · Antioxidants · doi:10.3390/antiox10121924 · Cited by 28
“These cells are alive and primarily contribute to tissue stress responses through age-related secretory phenotypes [29,30].”
BackgroundDynamics of Senescent Cell Formation and Retention Revealed by p14ARF Induction in the Epidermis
Tokarsky-Amiel, R., Azazmeh, N., Helman, A., Stein, Y., Hassan, A., Maly, A., & Ben-Porath, I. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3730 · Cited by 21
“It has been shown that p53 in fact suppresses the senescence-associated secretory phenotype (SASP), and that p16 function does not influence it (41, 42).”
BackgroundAutophagy and senescence, converging roles in pathophysiology as seen through mouse models
(2021) · Advances in Cancer Research · doi:10.1016/bs.acr.2021.02.001 · Cited by 20
Rzeszutek, I., Cybularczyk‐Cecotka, M., Deręgowska, A., Stec, P., Wnuk, M., Kołodziej, O., Kałafut, J., Wawruszak, A., Witkowski, W., Litwinienko, G., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01664 · Cited by 25
Bouvier, D., Giguère, Y., Blanchon, L., Bujold, E., Pereira, B., Bernard, N., Gallot, D., Sapin, V., & Forest, J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00609 · Cited by 23
“Sterile inflammation is a feature of senescence-associated fetal membranes maturity and is characterized mostly by the presence of inflammatory biomarkers, growth factors, and matrix degrading enzymes (Coppe et al., 2008).”
BackgroundDo senescence markers correlate in vitro and in situ within individual human donors?
Waaijer, M. E. C., Gunn, D. A., van Heemst, D., Slagboom, P. E., Sedivy, J. M., Dirks, R. W., Tanke, H. J., Westendorp, R. G. J., & Maier, A. B. (2018) · Aging · doi:10.18632/aging.101389 · Cited by 21
“Considerable interest has also been given to the possible in vivo implications of senescence; by studying relevant functions, including embryonic development and attenuating liver fibrosis as well as consequences of senescence in animal models, notably age-related diseases, and tumorigenesis [4-8].”
BackgroundTargeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy
Tomimatsu, N., Cristofaro, L. F. M. D., Kanji, S., Samentar, L., Jordan, B. R., Kittler, R., Habib, A. A., Espíndola‐Netto, J. M., Tchkonia, T., Kirkland, J. L., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00201-x · Cited by 34
“Importantly, senescent stromal cells have been shown to promote the growth of neighboring tumor cells via SASP (Bavik et al, 2006; Coppe et al, 2006; Coppe et al, 2008; Demaria et al, 2017; Liu and Hornsby, 2007; Parrinello et al, 2005; Tsai et al, 2005).”
Wu, H. C., Mach, J., Gnjidic, D., Naganathan, V., Blyth, F., Waite, L. M., Handelsman, D. J., Couteur, D. G. L., & Hilmer, S. N. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac061 · Cited by 25
“Previous studies have demonstrated that inflammatory cytokines IL-6 and IL-8 are associated with the SASP response (12,24) and are related to frailty in older adults (21).”
BackgroundHypoxia-induced senescence contributes to the regulation of microenvironment in melanomas
Mo, J., Sun, B., Zhao, X., Gu, Q., Dong, X., Liu, Z., Ma, Y., Zhao, N., Tang, R., Liu, Y., et al. (2013) · Pathology - Research and Practice · doi:10.1016/j.prp.2013.07.004 · Cited by 24
Geng, Q., Wang, S., Heng, K., Zhai, J., Song, X., Xia, L., Wang, L., Lin, Q., Li, H., & Guo, Y. (2022) · Food & Function · doi:10.1039/d2fo01673g · Cited by 23
Pratsinis, H., Armatas, A. A., Dimozi, A., Lefaki, M., Vassiliu, P., & Kletsas, D. (2013) · Wound Repair and Regeneration · doi:10.1111/wrr.12110 · Cited by 21
Siebels, S., Czech‐Sioli, M., Spohn, M., Schmidt, C., Theiß, J., Indenbirken, D., Günther, T., Grundhoff, A. T., & Fischer, N. (2020) · mBio · doi:10.1128/mbio.00142-20 · Cited by 21
Measuring the Senescence-Associated Secretory Phenotype
Karras, A., Λιούλιος, Γ., Kantartzi, K. M., Fylaktou, A., Panagoutsos, S. A., & Stangou, M. J. (2025) · Biomedicines · doi:10.3390/biomedicines13092062 · Cited by 29
“For instance, Coppé et al. utilized ELISA to measure elevated levels of IL-6 and IL-8 in the conditioned media of human fibroblasts undergoing oncogene-induced senescence (OIS) [70].”
Saleh, T., Khasawneh, A. I., Himsawi, N. M., Abu-Raideh, J. A., Ejeilat, V., Elshazly, A. M., & Gewirtz, D. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415512 · Cited by 24
Bachman, J. A., Sorger, P. K., & Gyori, B. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/822668 · Cited by 28
“as determined by p53 stabilization and phosphorylation (see Figure S3 and Text S1 )” [19] (Table 2).”
MethodSkin Disease in Laminopathy-Associated Premature Aging
McKenna, T., Sola-Carvajal, A., & Eriksson, M. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.295 · Cited by 24
“E-mail: Maria.Eriksson.2@ki.se Received 8 January 2015; revised 12 June 2015; accepted 29 June 2015; published online 20 August 2015 Abbreviations: HGPS, Hutchinson–Gilford progeria syndrome; LBR, lamin B receptor; OMIM, Online Inheritance in Man; RD, restrictive dermopathy; SASP, senescence-associated secretory pheno…”
BackgroundThe Rbm38-p63 feedback loop is critical for tumor suppression and longevity
Jiang, Y., Xu, E., Zhang, J., Chen, M., Flores, E. R., & Chen, X. (2018) · Oncogene · doi:10.1038/s41388-018-0176-5 · Cited by 22
“However, recent studies suggest that senescent cells can secret proinflammatory cytokiens, which would change the tissue microenvironment and promote tumorigenesis (21, 29).”
Šímová, J., Sapega, O., Hornofova, T., Štěpánek, I., Kyjacová, L., Mikyšková, R., Indrová, M., Bieblová, J., Bubenik, J., Bártek, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10712 · Cited by 27
“These ‘bystander’ effects are mediated by numerous molecules produced by the senescent cells, commonly termed senescence-associated secretory phenotype (SASP; [5, 6]).”
BackgroundRudnicki, M., Pislaru, A., Rezvan, O., Rullman, E., Fawzy, A., Nwadozi, E., Roudier, E. A., Gustafsson, T. P., & Haas, T. L. (2022) · iScience · doi:10.1016/j.isci.2022.105811 · Cited by 26
Varela‐Nieto, I., Palmero, I., & Magariños, M. (2019) · Hearing Research · doi:10.1016/j.heares.2019.01.014 · Cited by 21
Clinical impact of epithelial–mesenchymal transition for cancer therapy
Mukerjee, N., Nag, S., Bhattacharya, B., Alexiou, A. T., Mirgh, D., Mukherjee, D., Adhikari, M. D., Anand, K., Muthusamy, R., Gorai, S., et al. (2024) · Clinical and Translational Discovery · doi:10.1002/ctd2.260 · Cited by 30
Higd-1a regulates the proliferation of pancreatic cancer cells through a pERK/p27KIP1/pRB pathway
An, H., Ryu, M., Jeong, H. J., Kang, M., Jeon, H.-M., Lee, J., Kim, Y. S., & Lee, H. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.007 · Cited by 24
Propagation of senescent phenotypes by extracellular HMGB1 is dependent on its redox state
Shin, J.-W., Jang, D., Kim, S. Y., Lee, J., Gil, T., Shim, E., Kim, J. Y., Kim, H. S., Conboy, M. J., Conboy, I. M., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156259 · Cited by 24
Ratushnyy, A. Y., Lobanova, M. V., & Buravkova, L. B. (2017) · Cell Biochemistry and Function · doi:10.1002/cbf.3267 · Cited by 21
“It is suppose that these effects are mainly associated with the exposure to IL‐6 and IL‐8.44 Thus, the ASC paracrine activity and its dependence on the expansion duration are the important cell characteristics that may reflect their physiological state and the ability to influence on other cells.”
BackgroundInfluentialBiomarkers of cellular senescence and major health outcomes in older adults
Cummings, S. R., Lui, L., Aversa, Z., Mau, T., Fielding, R. A., Atkinson, E. J., Patel, S., & LeBrasseur, N. K. (2024) · GeroScience · doi:10.1007/s11357-024-01474-9 · Cited by 28
Telomeres and aging: on and off the planet!
Mason, C. E., Sierra, M. A., Feng, H. J., & Bailey, S. M. (2024) · Biogerontology · doi:10.1007/s10522-024-10098-7 · Cited by 25
“…senescence also underlies significant phenotypes associated with aging; e.g., the senescence-associated secretory phenotype (SASP) promotes chronic inflammation (inflammaging) and drives degenerative pathologies and carcinogenesis (Campisi 2001, 2013; Campisi et al. 2001; Coppe et al. 2008).”
BackgroundCancer: evolutionary, genetic and epigenetic aspects
Lichtenstein, A. V. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0010-6 · Cited by 20
“The participants of the “rescue operation” include fibroblasts (Elenbaas and Weinberg 2001; Kalluri and Zeisberg 2006 ;O rimo et al.2005), tumor-associated macrophages ( Condeelis and Pollard 2006 ; P ollard2004 ;S ahai2007), tumor-infiltrating neutrophils (Ardi et al. 2007), stroma (Albini and Sporn 2007), bone marro…”
BackgroundTRIM28/KAP1 regulates senescence
Santos, J., & Gil, J. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.08.011 · Cited by 20
Molecular bridging of aging and cancer: A CARF link
Cheung, C., Kaul, S. C., & Wadhwa, R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05392.x · Cited by 21
Yo, K., & Rünger, T. M. (2018) · Aging · doi:10.18632/aging.101528 · Cited by 21
Suzuki, E., Takahashi, M., Oba, S., & Nishimatsu, H. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/754735 · Cited by 23
“These changes have been referred to as the senescence-associated secretory phenotype [14].”
BackgroundThe Role of Senescence-Associated Secretory Phenotype in Bone Loss
Zhu, R., Wan, H., Yang, H. S., Song, M., Chai, Y., & Yu, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.841612 · Cited by 23
3D TECA hydrogel reduces cellular senescence and enhances fibroblasts migration in wound healing
Younis, L. T., Hassan, M. I. A., Ali, T. B. T., & Bustami, T. J. (2017) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2017.12.003 · Cited by 22
“[61] Coppe JP , Patil CK , Rodier F , et al.”
BackgroundERCC1-deficient cells and mice are hypersensitive to lipid peroxidation
Czerwińska, J., Nowak, M., Wojtczak, P., Dziuban-Lech, D., Cieśla, J., Kołata, D., Gajewska, B., Barańczyk‐Kuźma, A., Robinson, A. R., Shane, H. L., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.05.088 · Cited by 23
New Trends in Aging Drug Discovery
Benhamú, B., Martín‐Fontecha, M., Vázquez‐Villa, H., López-Rodríguez, M. L., & Ortega‐Gutiérrez, S. (2022) · Biomedicines · doi:10.3390/biomedicines10082006 · Cited by 22
“Its composition varies according to the cell type and senescence cause, but there is a conserved core program that includes proinflammatory interleukins 6 and 8 (IL-6, IL-8) and monocyte chemoattractant protein 1 (MCP-1) [31].”
BackgroundZhang, H., Zhou, H., Shen, X. M., Lin, X., Zhang, Y., Sun, Y., Zhou, Y., Zhang, L., & Zhang, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1276707 · Cited by 27
Self-citationMarongiu, F., Serra, M. P., Sini, M., Angius, F., & Laconi, E. (2014) · Aging · doi:10.18632/aging.100631 · Cited by 21
“Moreover, cell senescence and SASP have been linked to chronic inflammation [29], adding yet another facet to the complex relationship between cancer, aging, and the immune response [30,31].”
BackgroundInfluentialCellular and molecular features of senescence in acute lung injury
Huidobro, C., Martín-Vicente, P., López‐Martínez, C., López-Alonso, I., Amado‐Rodríguez, L., Crespo, I., & Albaiceta, G. M. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111410 · Cited by 20
Lee, H. G., Roh, S., Kim, H. J., Kim, S., Hong, Y., Lee, G., & Jeon, O. H. (2022) · Nanoscale Horizons · doi:10.1039/d2nh00220e · Cited by 22
Yamagami, M., Otsuka, M., Kishikawa, T., Sekiba, K., Seimiya, T., Tanaka, E., Suzuki, T., Ishibashi, R., Ohno, M., & Koike, K. (2018) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-018-0030-6 · Cited by 24
Andriyanov, A. V., Portnoy, E., Koren, E., Inesa, S., Eyal, S., Goldberg, S. N., & Barenholz, Y. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.018 · Cited by 22
“Thus proliferative and immune senescence generates condition for tumor progression [42] and promote invasiveness and transition of pre-cancer cells [43].”
BackgroundBalamurli, G., Liew, A. Q. X., Tee, W., & Pervaiz, S. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103441 · Cited by 25
Cellular senescence in the cholangiopathies
Bogert, P. S. T., O’Hara, S. P., & LaRusso, N. F. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000805 · Cited by 21
“The hypersecretion of bioactive molecules, or SASP, is another phenotypic feature of many senescent cells [6,30].”
BackgroundHypophosphorylated pRb knock‐in mice exhibit hallmarks of aging and vitamin C‐preventable diabetes
Jiang, Z., Li, H., Schroer, S. A., Voisin, V., Ju, Y., Pacal, M., Erdmann, N., Shi, W., Chung, P. E. D., Deng, T., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2020106825 · Cited by 19
Hou, C.-Y., Ma, C.-Y., Lin, Y.-J., Huang, C., Wang, H., & Yuh, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012100 · Cited by 22
“The senescenceassociated β-galactosidase (SA-β-gal), which is overexpressed in senescent cells, has been widely used as a marker of cellular senescence [44].”
BackgroundKRAS Mutant Tumor Subpopulations can Subvert Durable Responses to Personalized Cancer Treatments
Parsons, B. L., & Myers, M. B. (2013) · Personalized Medicine · doi:10.2217/pme.13.1 · Cited by 22
Pacifico, F., Mellone, S., D’Incalci, M., Stornaiuolo, M., Leonardi, A., & Crescenzi, E. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115159 · Cited by 20
Urothelial Senescence in the Pathophysiology of Diabetic Bladder Dysfunction—A Novel Hypothesis
Klee, N., McCarthy, C. G., Lewis, S., McKenzie, J., Vincent, J., & Webb, R. C. (2018) · Frontiers in Surgery · doi:10.3389/fsurg.2018.00072 · Cited by 25
“Recruitment of immune cells depend on senescent secretory activity known as the senescence-associated secretory phenotype (SASP), allowing the secretion of proinflammatory cytokines and chemokines, reactive oxygen species (ROS), growth factors, and proteases into the local tissue microenvironment through autocrine and…”
BackgroundMehdipour, M., Etienne, J., Liu, C., Mehdipour, T., Kato, C., Conboy, M. J., Conboy, I. M., & KIPROV, D. D. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103162 · Cited by 22
The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence
Barnoud, T., Schmidt, M., Donninger, H., & Clark, G. J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.030 · Cited by 27
“Perhaps the most prominent cytokine of the SASP is interleukin-6 (IL-6).”
InfluentialChen, B., Liang, Y., Chen, L., Wei, Y., Li, Y., Zhao, W., & Wu, J. (2018) · Journal of Cancer · doi:10.7150/jca.23967 · Cited by 22
“First, SASP factors support tumor cell invasion and metastasis by disrupting and remodeling tissue structure [7, 17].”
BackgroundBurel, S. L., Thépenier, C., Boutin, L., Lataillade, J., & Peltzer, J. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0184 · Cited by 23
Tissue Engineering and Regenerative Medicine Therapies for Cell Senescence in Bone and Cartilage
Zhang, Q., Nettleship, I., Schmelzer, E., Gerlach, J. C., Zhang, X., Wang, J., & Liu, C. (2019) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2019.0215 · Cited by 20
Sumoylation in Cellular Senescence and Aging
Gong, L., Sun, Q., & Li, D. (2017) · Current Molecular Medicine · doi:10.2174/1566524016666161223104915 · Cited by 19
Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies?
Chen, F., Qi, X., Qian, M., Dai, Y., & Sun, Y. (2014) · Protein & Cell · doi:10.1007/s13238-014-0097-1 · Cited by 23
“Characterized with either “senescence-associated secretory phenotype” (SASP) (Coppe et al., 2008) or genome-wide “senescence-messaging secretome” (SMS) (Kuilman and Peeper 2009), damaged cells significantly alter surrounding microenvironments through robust secretion of soluble factors.”
InfluentialSelf-citationThompson, E. L., Hu, J., & Niedernhofer, L. J. (2021) · Cancers · doi:10.3390/cancers13092241 · Cited by 20
“Parallels between (A) Non-genetic mechanisms contributing to melanoma drug resistance and (B) Cellular senescence pro-tumor characteristics. p16INK4a: cyclin-dependent kinase inhibitor 2A; p21: cyclin-dependent kinase inhibitor 1A; p53: tumor protein p53; ROS: reactive oxygen species, SA- β-gal: senescence-associated…”
BackgroundInfluentialThe Role of Telocytes and Telocyte-Derived Exosomes in the Development of Thoracic Aortic Aneurysm
Aschacher, T., Aschacher, O., Schmidt, K., Enzmann, F., Eichmair, E., Winkler, B. M., Arnold, Z., Nagel, F., Podesser, B. K., Mitterbauer, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094730 · Cited by 20
“This repetitive cellular stress leads to cellular senescence, which includes the secretion of pro-inflammatory cytokines, growth factors, and extracellular matrix degradation proteins [3].”
BackgroundTang, Q., Xing, X., Huang, H., Yang, J., Li, M., Xu, X., Gao, X., Cheng, L., Tian, W., & Liao, L. (2024) · GeroScience · doi:10.1007/s11357-024-01068-5 · Cited by 21
“A small number of senescent cells accumulated in tissue could cause extensive local and systemic dysfunction [7].”
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.